Imatinib use either pre- or post-allogeneic hematopoietic cell transplantation (allo-HCT) does not increase cardiac toxicity in chronic myelogenous leukemia patients
- M. J. Burke
- , B. Trotz
- , X. Luo
- , D. J. Weisdorf
- , K. S. Baker
- , J. E. Wagner
- , M. R. Verneris
Research output: Contribution to journal › Article › peer-review
12
Link opens in a new tab
Scopus
citations